Accessibility Menu
Innate Pharma logo

Innate Pharma(OTC) IPHYF

Market Cap$154.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-51%
5 Year-57%
1 Year+14%
1 Month+10%
$1.65
+0%
+0.00Today
Innate Pharma last closing stock price
MetricPriceDate
Last closeUSD 1.652026-05-27
Innate Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-26.67%USD 2.252026-05-14
1 month+10%USD 1.502026-04-14
3 month-23.43%USD 2.162026-02-18
Year to date-23.43%USD 2.162025-12-16
1 year+13.79%USD 1.452025-05-13
3 year-43.69%USD 2.932023-05-10
5 year-56.58%USD 3.802021-05-13
Since inception-51.11%USD 3.382013-06-05

Innate Pharma Financials at a Glance

Market Cap

$154.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€18.60M

Net Income (TTM)

-€98.64M

EPS (TTM)

-$0.61

P/E Ratio

-2.68

Dividend

$0.00

Beta (Volatility)

-0.01 (Low)

Price

$1.65

Volume

6,700

Open

$1.65

Previous Close

$1.65

Daily Range

$1.65 - $1.65

52-Week Range

$1.31 - $2.25

Estimated Earnings Date

Sep 17, 2026

IPHYF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innate Pharma

Innate Pharma S.A. is a biotechnology firm based in Marseille, France, specializing in the discovery and development of innovative antibody-based therapies for various oncological conditions. The company is actively advancing its clinical pipeline, which includes several promising candidates aimed at addressing unmet medical needs in cancer treatment.

Products and Services
  • Lacutamab (IPH4102): Anti-KIR3DL2 antibody in Phase II trials for lymphomas
  • Monalizumab: Immune checkpoint inhibitor in Phase III trials for advanced solid tumors
  • Avdoralimab (IPH5401): Monoclonal antibody in Phase II trials for inflammatory conditions
Growth Outlook
  • Strong pipeline with multiple candidates in advanced clinical stages
  • Strategic partnerships with major pharmaceutical companies enhance market reach
  • Focus on innovative therapies positions the company for future growth
Financial Highlights
  • Recent quarterly revenue of €1,115,581, showing potential for growth
  • Cash and short-term investments of €34,297,149 provide operational stability
  • Operating expenses of €32,037,995 reflect ongoing investment in R&D
Innate Pharma S.A. operates in a dynamic biotechnology sector, focusing on developing therapies that target critical areas in oncology and inflammation. The company's clinical pipeline is robust, with several candidates in various stages of development, indicating a commitment to innovation and addressing significant medical needs. Strategic alliances with established pharmaceutical companies further bolster its market position, providing access to resources and expertise that can accelerate development timelines. Financially, the company is navigating a challenging landscape, with recent quarterly revenue indicating potential for growth, while maintaining a solid cash position to support ongoing research and development efforts. The focus on innovative therapies and strategic partnerships positions Innate Pharma favorably for future opportunities in the biotechnology market.
AI Generated • Jul 4, 2026

Industry

Biotechnology

Sector

Health Care

Employees

163

CEO

Jonathan Dickinson, MBA

Website

www.innate-pharma.com

Headquarters

Marseille, PA 13009, FR

IPHYF Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-2058.02%

Net Income Margin

-1764.51%

Return on Equity

593.93%

Return on Capital

-6150.17%

Return on Assets

-78.41%

Earnings Yield

-37.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$154.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

93.90M

Volume

6.70K

Avg. Volume

111.29

Financials (TTM)

Gross Profit

-€2.60M

Operating Income

-€105.00M

EBITDA

-€90.56M

Operating Cash Flow

-€59.64M

Capital Expenditure

-€530.97K

Free Cash Flow

-€60.17M

Cash & ST Invst.

€34.30M

Total Debt

€22.56M

Innate Pharma Performance Analysis

Innate Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 52,107,307264.0%
20232023-12-31EUR 56,110,9817.7%
20242024-12-31EUR 13,653,101-75.7%
20252025-12-31EUR 3,145,347-77.0%
Innate Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-42.4%
Q42024-12-31-97.8%
Q22025-06-301660.9%
Q42025-12-31-77.0%
Innate Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.77-2.3%
20232023-12-31EUR -0.10-86.7%
20242024-12-31EUR -0.66549.2%
20252025-12-31EUR -0.62-6.2%
Innate Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-158.3%
Q42024-12-313.2%
Q22025-06-3016.7%
Q42025-12-31-20.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

€1.12M

-94.8%

Gross Profit

€438.84K

+114.0%

Gross Margin

39.34%

N/A

Market Cap

$154.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$856.02K

N/A

Employees

181

N/A

Net Income

-€27.82M

-199.6%

EBITDA

-€18.59M

-78.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

€34.30M

-62.9%

Total Debt

€22.56M

-43.4%

Accounts Receivable

€7.61M

-83.6%

Inventory

€0.00

N/A

Long Term Debt

€13.77M

-55.5%

Short Term Debt

€8.80M

-1.5%

Return on Assets

-78.41%

N/A

Return on Invested Capital

-2.20%

N/A

Free Cash Flow

-€21.66M

-2.5%

Operating Cash Flow

-€21.58M

-2.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MLLCFMolecular Partners AG
$3.80+0.00%
SCNLFScancell Holdings plc
$0.13+0.00%
NDTPNDT Pharmaceuticals Inc.
$0.55+22.22%
JWCTFJW (Cayman) Therapeutics Co. Ltd
$0.20+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$8.41-0.06%
TAT&T
$23.94-0.03%
SMRNuScale Power
$7.59-0.08%
ORCLOracle
$117.74-0.02%

Questions About IPHYF

What is the current price of Innate Pharma?

Innate Pharma is trading at $1.65 per share.

What is the 52-week range for Innate Pharma?

Over the past 52 weeks, Innate Pharma has traded between $1.31 and $2.25.

How much debt does Innate Pharma have?

As of the most recent reporting period, Innate Pharma reported total debt of €26.51M.

How much cash does Innate Pharma have on hand?

Innate Pharma reported €32.99M in cash and cash equivalents in its most recent financial results.

What is Innate Pharma’s dividend yield?

Innate Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services